ProfileGDS5678 / 1423245_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 84% 83% 85% 84% 85% 82% 83% 85% 86% 86% 86% 88% 88% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.228584
GSM967853U87-EV human glioblastoma xenograft - Control 26.0926483
GSM967854U87-EV human glioblastoma xenograft - Control 36.4116385
GSM967855U87-EV human glioblastoma xenograft - Control 46.4634184
GSM967856U87-EV human glioblastoma xenograft - Control 56.4892385
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7508682
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9335983
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.3430585
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.513986
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.5646486
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.4985386
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8327888
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.8823988
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.9637689